Q-omics provides the consensus-scored MTCYBP15 profile across patient tissues and cancer cell-line models. MTCYBP15 expression is associated with patient survival in 12 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, MTCYBP15 is differentially expressed in 3, with the highest sampling consensus in KIRP. Additionally, MTCYBP15 RNA expression shows 6,875 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight UCS, KIRP, and TGCT as cancer lineages where MTCYBP15 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTCYBP15 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTCYBP15 survival associations across molecular data types. MTCYBP15 RNA expression shows survival associations in the most cancer types (12). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTCYBP15 RNA expression–survival associations across cancer types. High MTCYBP15 expression shows unfavorable associations in UCS, STAD, BRCA, HNSC, READ and DLBC. The UCS Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .002). Together, the overview and detailed table identify UCS as the clearest survival context for MTCYBP15 RNA expression.
This table summarizes MTCYBP15 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 3. The strongest signals are observed in KIRP for RNA.
This table ranks reproducible tumor–normal expression differences for MTCYBP15. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTCYBP15 shows lower tumor expression in KIRP, ESCA and KIRC. The KIRP box plot shows higher MTCYBP15 RNA expression in normal versus tumor tissue (log2 FC = −0.022, t-test p = .026).
This table shows molecular features associated with MTCYBP15 in patient tissues and cancer cell lines. In patient samples, MTCYBP15 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
